25 min

Potential Rett syndrome drug shows promising results in phase 3 trial Vanderbilt Kennedy Center

    • Science

The Promise of Discovery Season 2, Episode 7:

This episode features a discussion of the need for meaningful therapies in Rett syndrome (RTT), and highlights the Lavender™ study, a phase 3, 12-week, double-blind, randomized, placebo-controlled study of the drug trofinetide in 187 young females, ages 5 to 20, with Rett syndrome. Investigators discuss public, top-level results of the potential first-of-its-kind drug to treat the symptoms of RTT, and share the hope that this trial paves the way for other successful trials in RTT and related disorders.

VKC Researchers:

Jeffrey L. Neul, M.D., Ph.D., Annette Schaffer Eskind Chair and Director, Vanderbilt Kennedy Center; Professor of Pediatrics, Division of Neurology, Pharmacology, and Special Education

Cary Fu, M.D., Assistant Professor of Pediatrics, Pediatric Neurology

The Promise of Discovery Season 2, Episode 7:

This episode features a discussion of the need for meaningful therapies in Rett syndrome (RTT), and highlights the Lavender™ study, a phase 3, 12-week, double-blind, randomized, placebo-controlled study of the drug trofinetide in 187 young females, ages 5 to 20, with Rett syndrome. Investigators discuss public, top-level results of the potential first-of-its-kind drug to treat the symptoms of RTT, and share the hope that this trial paves the way for other successful trials in RTT and related disorders.

VKC Researchers:

Jeffrey L. Neul, M.D., Ph.D., Annette Schaffer Eskind Chair and Director, Vanderbilt Kennedy Center; Professor of Pediatrics, Division of Neurology, Pharmacology, and Special Education

Cary Fu, M.D., Assistant Professor of Pediatrics, Pediatric Neurology

25 min

Top Podcasts In Science

Hidden Brain
Alie Ward
Neil deGrasse Tyson
Sam Harris
Vox
PRX and Greater Good Science Center